Abiopharma

🔍 Jones Cecilia (Executive)

Company: AGIOS PHARMACEUTICALS, INC. (AGIO)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Acquired 8,500 shares of Common stock (Direct)
  Date: 2026-04-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 58,139.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,141 shares of Common stock at $34.71 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,998.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 8,500 shares of Performance share units (Derivative)
  Date: 2026-04-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,500.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Includes 311 shares purchased through the Company's employee stock purchase plan.
• F2: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024.
• F3: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
• F4: The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.